BioCentury | Jun 6, 2020
Finance

Daily Chart: NASDAQ’s dazzling debuts

...Inc. Revolution Medicines Inc. Beam Therapeutics Inc. PPD Inc. Schroedinger Inc. Arcutis Biotherapeutics Inc. Anpac Bio-Medical Science Co. Ltd. Black Diamond Therapeutics Inc. Annovis...
BioCentury | Apr 3, 2020
Deals

Servier adds mAb platform via takeout of former European biotech darling Symphogen

...series E round, which at the time was the largest European venture round ever (see “Symphony...
BioCentury | Feb 15, 2020
Management Tracks

Immunomedics names Itri CMO; plus Hua, GenMark, AAM, Vividion, Sophia Genetics, Enterprise, Encoded, Palleon and more

...efficiently generate real-world data, hired Neal Bibeau as CEO. He was president and CEO of Symphony...
BioCentury | Jan 30, 2020
Financial News

Jan. 29 Financial Quick Takes: Black Diamond prices upsized IPO; plus Biohaven, Denali, Concert follow-ons, Lyra, Annovis, Histogen-Conatus and CellFE

...months of therapy to sinonasal passages. First-day pop for microcap Annovis Shares of neurodegeneration company Annovis...
...rose $3.59 (69%) to close at $9.59 after the biotech priced its IPO at $6. Annovis...
BioCentury | Oct 4, 2019
Finance

Biotechs likely to flood IPO market ahead of 2020 election

...Up to $23 Dev (device) Jiangsu Jibeier Pharmaceutical Co. Ltd. (Shanghai) 7/3/19 $100.2 Mkt (drug) Annovis...
BioCentury | Jul 10, 2019
Company News

Management tracks: Maze, Tiaki, NED, Annexon and more

...and Mick O'Quigley to VP, development operations from head of clinical operations. Neurodegenerative disease company Annovis...
...CFO. He was SVP and CFO of Safeguard Scientifics Inc. (NYSE:SFE). Jonathan Block, Associate Editor Annexon Biosciences Inc. Annovis Inc. Ideaya...
BioCentury | Aug 17, 2017
Finance

Built to purpose

...Venture raised Purchase amount Option date Exercise date Symphony Icon Inc. Lexicon Pharmaceuticals Inc. (NASDAQ:LXRX) Symphony...
BioCentury | Sep 5, 2016
Clinical News

Tesevatinib: Phase II started

...tesevatinib under a 2010 deal with Symphony Evolution. Kadmon Holdings Inc. (NYSE:KDMN), New York, N.Y. Symphony...
BioCentury | Apr 11, 2016
Company News

Gyros, Protein Technologies deal

...and manufacturing of biotherapeutics. Gyros’ products include its Gyrolab xP workstation. Protein’s products include its Symphony...
BioCentury | Jan 25, 2016
Clinical News

Tesevatinib: Phase II started

...tesevatinib under a 2010 deal with Symphony Evolution. Kadmon Corp. LLC , New York, N.Y. Symphony...
Items per page:
1 - 10 of 260
BioCentury | Jun 6, 2020
Finance

Daily Chart: NASDAQ’s dazzling debuts

...Inc. Revolution Medicines Inc. Beam Therapeutics Inc. PPD Inc. Schroedinger Inc. Arcutis Biotherapeutics Inc. Anpac Bio-Medical Science Co. Ltd. Black Diamond Therapeutics Inc. Annovis...
BioCentury | Apr 3, 2020
Deals

Servier adds mAb platform via takeout of former European biotech darling Symphogen

...series E round, which at the time was the largest European venture round ever (see “Symphony...
BioCentury | Feb 15, 2020
Management Tracks

Immunomedics names Itri CMO; plus Hua, GenMark, AAM, Vividion, Sophia Genetics, Enterprise, Encoded, Palleon and more

...efficiently generate real-world data, hired Neal Bibeau as CEO. He was president and CEO of Symphony...
BioCentury | Jan 30, 2020
Financial News

Jan. 29 Financial Quick Takes: Black Diamond prices upsized IPO; plus Biohaven, Denali, Concert follow-ons, Lyra, Annovis, Histogen-Conatus and CellFE

...months of therapy to sinonasal passages. First-day pop for microcap Annovis Shares of neurodegeneration company Annovis...
...rose $3.59 (69%) to close at $9.59 after the biotech priced its IPO at $6. Annovis...
BioCentury | Oct 4, 2019
Finance

Biotechs likely to flood IPO market ahead of 2020 election

...Up to $23 Dev (device) Jiangsu Jibeier Pharmaceutical Co. Ltd. (Shanghai) 7/3/19 $100.2 Mkt (drug) Annovis...
BioCentury | Jul 10, 2019
Company News

Management tracks: Maze, Tiaki, NED, Annexon and more

...and Mick O'Quigley to VP, development operations from head of clinical operations. Neurodegenerative disease company Annovis...
...CFO. He was SVP and CFO of Safeguard Scientifics Inc. (NYSE:SFE). Jonathan Block, Associate Editor Annexon Biosciences Inc. Annovis Inc. Ideaya...
BioCentury | Aug 17, 2017
Finance

Built to purpose

...Venture raised Purchase amount Option date Exercise date Symphony Icon Inc. Lexicon Pharmaceuticals Inc. (NASDAQ:LXRX) Symphony...
BioCentury | Sep 5, 2016
Clinical News

Tesevatinib: Phase II started

...tesevatinib under a 2010 deal with Symphony Evolution. Kadmon Holdings Inc. (NYSE:KDMN), New York, N.Y. Symphony...
BioCentury | Apr 11, 2016
Company News

Gyros, Protein Technologies deal

...and manufacturing of biotherapeutics. Gyros’ products include its Gyrolab xP workstation. Protein’s products include its Symphony...
BioCentury | Jan 25, 2016
Clinical News

Tesevatinib: Phase II started

...tesevatinib under a 2010 deal with Symphony Evolution. Kadmon Corp. LLC , New York, N.Y. Symphony...
Items per page:
1 - 10 of 260